Baricitinib re-submission within five months

30 August 2017
2019_biotech_test_vial_discovery_big

A potential rheumatoid arthritis (RA) blockbuster could yet be available in the USA within the next year after its manufacturers were given the go-ahead to complete a re-submission package without the need for a new clinical study.

The news led shares in both pharma major Eli Lilly (NYSE: LLY) and its biotech partner Incyte Corporation (Nasdaq: INCY) to open up by single-digit percentages in Wednesday’s trading.

The US companies announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases in 2009, and in 2016 they made submissions for marketing approval for its use as a treatment of RA in the USA, the European Union (EU) and Japan.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology